Strategic Priorities

Our Priorities

Three interlocking initiatives that address the most critical gaps in post-acute and chronic condition research โ€” from evidence synthesis to biological infrastructure to clinical recognition.

๐Ÿ”ญ
Priority 01
๐Ÿ’Š

Repurposed Drugs for Chronic Conditions

Publishing systematic reviews and evidence syntheses on approved drugs with therapeutic promise for post-acute conditions โ€” and building clinical trial protocols to test them.

  • AI-assisted drug candidate identification
View Chronic Disease Evidence Summary โ†’
Priority 02
๐Ÿงฌ

Post-Viral Syndromes Biobank

Establishing a curated biological sample and data repository from post-viral syndrome patients โ€” providing the standardised infrastructure that reproducible biomarker research requires.

  • Standardised sample collection protocols
  • Rich clinical annotation and longitudinal design
Learn More โ†’
Priority 03
๐Ÿ“‹

Post-Viral Syndromes: Diagnosis and Treatment Guidelines

Developing evidence-based diagnostic criteria and educational resources for post-viral syndromes โ€” giving clinicians a structured framework to identify, classify, and treat affected patients.